MBAI

Company Overview — What Does Check-Cap Ltd Do?

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel. Check-Cap Ltd (MBAI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Alex Ovadia and employs approximately 80 people. With a market capitalization of $13M, MBAI is one of the notable companies in the Healthcare sector.

Check-Cap Ltd (MBAI) Stock Rating — Hold (April 2026)

As of April 2026, Check-Cap Ltd receives a Hold rating with a composite score of 38.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.MBAI ranks #1,399 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Check-Cap Ltd ranks #114 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MBAI Stock Price and 52-Week Range

Check-Cap Ltd (MBAI) currently trades at $1.65. The 52-week high for MBAI is $3.92, which means the stock is currently trading -57.9% from its annual peak. The 52-week low is $0.59, putting the stock 178.2% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is MBAI Overvalued or Undervalued? — Valuation Analysis

Check-Cap Ltd (MBAI) carries a value factor score of 3/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.38x, compared to the Healthcare sector average of 23.63x — a discount of 98%.

At current multiples, Check-Cap Ltd trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Check-Cap Ltd Profitability — ROE, Margins, and Quality Score

Check-Cap Ltd (MBAI) earns a quality factor score of 33/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -26683.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MBAI Debt, Balance Sheet, and Financial Health

Balance sheet data for MBAI is evaluated through our stability factor. Total debt on the balance sheet is $0. Cash and equivalents stand at $0.

MBAI has a beta of 1.12, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Check-Cap Ltd is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Check-Cap Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, Check-Cap Ltd reported revenue of $0 and earnings per share (EPS) of $4.30. Net income for the quarter was $-25M. Operating income came in at $-26M.

In FY 2024, Check-Cap Ltd reported revenue of $0 and earnings per share (EPS) of $4.30. Net income for the quarter was $-25M. Operating income came in at $-26M.

In FY 2023, Check-Cap Ltd reported revenue of $0 and earnings per share (EPS) of $3.00. Net income for the quarter was $-18M. Operating income came in at $-19M.

In FY 2022, Check-Cap Ltd reported revenue of $0 and earnings per share (EPS) of $3.37. Net income for the quarter was $-19M. Operating income came in at $-20M.

Over the past 8 quarters, Check-Cap Ltd has experienced revenue contraction from $0 to $0. Investors analyzing MBAI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MBAI Dividend Yield and Income Analysis

Check-Cap Ltd (MBAI) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MBAI Momentum and Technical Analysis Profile

Check-Cap Ltd (MBAI) has a momentum factor score of 55/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 62/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

MBAI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Check-Cap Ltd (MBAI) ranks #114 out of 838 stocks based on the Blank Capital composite score. This places MBAI in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MBAI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MBAI vs S&P 500 (SPY) comparison to assess how Check-Cap Ltd stacks up against the broader market across all factor dimensions.

MBAI Next Earnings Date

No upcoming earnings date has been announced for Check-Cap Ltd (MBAI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MBAI? — Investment Thesis Summary

Check-Cap Ltd presents a balanced picture with arguments on both sides. The quality score of 33/100 flags below-average profitability. The value score of 3/100 indicates premium valuation. High volatility (stability score 22/100) increases portfolio risk.

In summary, Check-Cap Ltd (MBAI) earns a Hold rating with a composite score of 38.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MBAI stock.

Related Resources for MBAI Investors

Explore more research and tools: MBAI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MBAI head-to-head with peers: MBAI vs AZN, MBAI vs SLGL, MBAI vs VMD.